# Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

> **NCT00370071** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 39 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)

## Key facts

- **NCT ID:** NCT00370071
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00370071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00370071, "Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00370071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*